Signal from the log
Aptatek Biosciences
Undisclosed · Diagnostics
Aptatek Biosciences développe PheCheck, un lecteur de poche et une cartouche qui mesurent la phénylalanine dans une goutte de sang à domicile, pour les patients atteints de phénylcétonurie. Le dispositif a la désignation Breakthrough de la FDA ; la levée, menée par Canterbury Scientific et Longview Innovation, n'a pas de montant public.
Spotted Amount read from the headline
Announced on , logged by the watch of 29 September 2026.
- Operation
- Funding round
- Stage
- Undisclosed
- Sector
- Diagnostics
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by Canterbury Scientific , Longview Innovation
What is missing before publishing
- No public amount. A missing amount is never estimated or inferred from a filing.
Provenance
Source businesswire
Logged on 29 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.